Ketamine in the Treatment of Suicidal Depression

Randomised, double-blind, parallel-group trial in depressed adults with suicidal ideation comparing a single IV infusion of ketamine (0.5 mg/kg) versus midazolam (0.02 mg/kg); infusions administered over ~40 minutes.

Nonresponders who received midazolam may be offered a second ketamine infusion; participants receive weekly follow-up interviews for 6 weeks and may be offered standard antidepressant treatment thereafter. Study requires brief inpatient admission at NYSPI.